These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11983866)

  • 1. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
    Hodi FS; Schmollinger JC; Soiffer RJ; Salgia R; Lynch T; Ritz J; Alyea EP; Yang J; Neuberg D; Mihm M; Dranoff G
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6919-24. PubMed ID: 11983866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma.
    Zhou J; Gupta M; Wu X; Yoon C; Giobbie-Hurder A; Hodi FS
    Cancer Immunol Res; 2015 Jan; 3(1):59-67. PubMed ID: 25387894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
    Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
    J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Dranoff G; Jaffee E; Lazenby A; Golumbek P; Levitsky H; Brose K; Jackson V; Hamada H; Pardoll D; Mulligan RC
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3539-43. PubMed ID: 8097319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
    Schmollinger JC; Vonderheide RH; Hoar KM; Maecker B; Schultze JL; Hodi FS; Soiffer RJ; Jung K; Kuroda MJ; Letvin NL; Greenfield EA; Mihm M; Kutok JL; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3398-403. PubMed ID: 12626761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
    Yu JS; Burwick JA; Dranoff G; Breakefield XO
    Hum Gene Ther; 1997 Jun; 8(9):1065-72. PubMed ID: 9189764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
    Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
    Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
    Fonseca C; Soiffer R; Ho V; Vanneman M; Jinushi M; Ritz J; Neuberg D; Stone R; DeAngelo D; Dranoff G
    Blood; 2009 Feb; 113(8):1681-8. PubMed ID: 19008459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Lynch T; Mihm M; Jung K; Rhuda C; Schmollinger JC; Hodi FS; Liebster L; Lam P; Mentzer S; Singer S; Tanabe KK; Cosimi AB; Duda R; Sober A; Bhan A; Daley J; Neuberg D; Parry G; Rokovich J; Richards L; Drayer J; Berns A; Clift S; Cohen LK; Mulligan RC; Dranoff G
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13141-6. PubMed ID: 9789055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.